The estimated Net Worth of Douglas J. Hughes is at least $2.24 Million dollars as of 27 August 2021. Mr. Hughes owns over 18,247 units of Immunovant Inc stock worth over $1,697,885 and over the last 5 years he sold IMVT stock worth over $82,500. In addition, he makes $458,304 as Independent Director at Immunovant Inc.
Sign up
Mr. Hughes IMVT stock SEC Form 4 insiders trading
Douglas has made over 2 trades of the Immunovant Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 18,247 units of IMVT stock worth $150,355 on 27 August 2021.
The largest trade he's ever made was buying 18,247 units of Immunovant Inc stock on 27 August 2021 worth over $150,355. On average, Douglas trades about 1,519 units every 9 days since 2019. As of 27 August 2021 he still owns at least 58,447 units of Immunovant Inc stock.
You can see the complete history of Mr. Hughes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Douglas Hughes biography
Douglas J. Hughes serves as Independent Director of the Company. Since the closing of the Business Combination in December 2019, Mr. Hughes has served as a member of Immunovant’s board of directors. Since 2020, Mr. Hughes has served as part-time Chief Financial Officer for Medolac Laboratories, a company providing human milk-based products to hospitals. Since 2019, Mr. Hughes has served as Chief Financial Officer of Calyxo Inc. (formerly Kalera Medical, Inc.), an early stage medical device company. From 2011 until 2018, Mr. Hughes was Chief Financial Officer for NeoTract, Inc., a Urology company. Prior to that time, he served as Chief Financial Officer and Chief Operating Officer for Nellix, Inc., an endovascular graft biotechnology company. Before joining Nellix, Inc., Mr. Hughes served as Chief Financial officer for Evalve Inc., a medical device company, from 2009 until 2010. Prior to 2009, Mr. Hughes held a variety of senior finance management positions at Boston Scientific, Guidant Corporation and The Clorox Company. Mr. Hughes is currently a director at Calyxo Inc. (formerly Kalera Medical, Inc.), a position held since 2018. Mr. Hughes received a B.S. in Finance from San Francisco State University and an M.B.A. from University of Chicago. Our board of directors believes that Mr. Hughes’ expertise in successfully leading high-growth companies, his experience in strategic planning and his knowledge of mergers and acquisitions qualifies him to serve as a member of our board of directors.
What is the salary of Douglas Hughes?
As the Independent Director of Immunovant Inc, the total compensation of Douglas Hughes at Immunovant Inc is $458,304. There are 6 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
How old is Douglas Hughes?
Douglas Hughes is 58, he's been the Independent Director of Immunovant Inc since 2019. There are 5 older and 9 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
What's Douglas Hughes's mailing address?
Douglas's mailing address filed with the SEC is 320 W 37TH STREET, 6TH FLOOR, , NEW YORK, NY, 10018.
Insiders trading at Immunovant Inc
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann, and Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
What does Immunovant Inc do?
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
What does Immunovant Inc's logo look like?
Complete history of Mr. Hughes stock trades at Immunovant Inc and Eargo
Immunovant Inc executives and stock owners
Immunovant Inc executives and other stock owners filed with the SEC include:
-
Peter Salzmann,
Chief Executive Officer, Director -
Pamela Connealy,
Chief Financial Officer -
Dr. Peter Salzmann M.B.A., M.D.,
CEO & Director -
Frank Torti,
Chairman of the Board -
Dr. Julia G. Butchko Ph.D.,
Chief Devel. & Technology Officer -
Andrew Fromkin,
Independent Director -
Douglas Hughes,
Independent Director -
Atul Pande,
Independent Director -
Dr. Frank M. Torti M.B.A., M.D., MBA,
Exec. Chairperson of the Board -
George Migausky,
Independent Director -
Eric Venker,
Director -
W. Bradford Middlekauff,
General Counsel -
Michael Elliott,
Chief Scientific Officer -
Julia Butchko,
Chief Development and Technology Officer -
Dr. William L. Macias M.D., Ph.D.,
Chief Medical Officer -
Lauren Schrier M.B.A.,
VP of Marketing -
Mark S. Levine,
Chief Legal Officer & Corp. Sec. -
Tom Dorney M.B.A., M.S.,
Director of Investor Relations & Strategy -
Eva Renee Barnett M.B.A.,
Chief Financial Officer -
Sciences Holdings, Llc Health,
10% owner -
Robert K Zeldin,
Chief Medical Officer -
Myrtle S Potter,
Director -
Jay S Stout,
Chief Technology Officer -
Rita Jain,
Chief Medical Officer -
William L. Macias,
Chief Medical Officer -
Eva Renee Barnett,
Chief Financial Officer -
Mark S. Levine,
Chief Legal Officer -
Sciences Ltd. Roivant,
-
Michael Geffner,
Chief Medical Officer